Skip to main content
    M

    MiMedx Group Inc (MDXG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.03 (-0.93%)

    Market Cap: $468.42M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MiMedx Group Inc (MDXG) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to MiMedx Group are DiaMedica Therapeutics (DMAC), CorMedix (CRMD) and Editas Medicine (EDIT). By market cap, MiMedx Group ranks 7th of the 13 companies on this page; Immix Biopharma (IMMX) is the largest at $657.09M.

    Peer Comparison

    MDXG's revenue growth of -45.2% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    MiMedx Group (MDXG)$468.42M106.0x1.5x-6.3%N/A-45.2%0.00%
    DiaMedica Therapeutics Inc (DMAC)$474.29MN/AN/A0.0%N/A0.0%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Editas Medicine Inc (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Orchestra BioMed Holdings Inc. (OBIO)$570.61MN/A14.7x-182.5%-97.0%-89.4%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Galectin Therapeutics Inc (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Peer median$458.23M6.3x4.7x-11.3%-14.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to MiMedx Group, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    DiaMedica Therapeutics Inc (DMAC)
    DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
    DMAC competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    Editas Medicine Inc (EDIT)
    Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases.
    EDIT competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Orchestra BioMed Holdings Inc. (OBIO)
    Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases.
    OBIO competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Galectin Therapeutics Inc (GALT)
    Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic...
    GALT competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors

    Frequently Asked Questions About MDXG

    Who are MiMedx Group's main competitors?

    The companies most similar to MiMedx Group include DiaMedica Therapeutics (DMAC), CorMedix (CRMD), Editas Medicine (EDIT), Prothena Corporation (PRTA) and Orchestra BioMed Holdings (OBIO), listed from the closest match.

    Who is MiMedx Group's biggest competitor?

    Immix Biopharma (IMMX) is the largest of the similar companies at $657.09M; DiaMedica Therapeutics (DMAC) is the closest match by business profile, size, sector and industry.

    How does MDXG stock compare with its competitors?

    MDXG's P/E is 106.0x against a peer median of 6.3x; its P/S is 1.5x against a peer median of 4.7x; its net margin is -6.3% against a peer median of -11.3%.

    Which of MiMedx Group's competitors pays a higher dividend?

    MiMedx Group pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is MiMedx Group bigger than its competitors?

    No. MiMedx Group is 7th by market cap among the 13 companies on this page; the largest is Immix Biopharma (IMMX) at $657.09M.